OTCMKTS:CVSICV Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CV Sciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.75 -0.09 (-10.71 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$0.73Now: $0.75▼$0.8650-Day Range$0.40MA: $0.61▼$1.1852-Week Range$0.25Now: $0.75▼$4.94Volume1.24 million shsAverage Volume979,049 shsMarket Capitalization$74.89 millionP/E RatioN/ADividend YieldN/ABeta0.35 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. This segment provides its hemp extract products in balms, sprays, drops, capsules, gummies, and softgel forms. It also sells raw materials to various customers that produce products for resale into the market in Europe. The Specialty Pharmaceuticals segment develops cannabinoids to treat a range of medical indications. Its product candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingCV Sciences has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.35, CV Sciences has a potential upside of 346.7% from its current price of $0.75.Amount of Analyst CoverageCV Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesCV Sciences has received 211 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCV Sciences has received 183 “underperform” votes. (Add your “underperform” vote.)Community SentimentCV Sciences has received 53.55% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CV Sciences and other stocks. Vote “Outperform” if you believe CVSI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CVSI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCV Sciences does not currently pay a dividend.Dividend GrowthCV Sciences does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CV Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,248.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 14.60% of the stock of CV Sciences is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CV Sciences are expected to grow in the coming year, from ($0.10) to $0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CV Sciences is -5.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CV Sciences is -5.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCV Sciences has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.93 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CVSI Previous SymbolNASDAQ:CVSI CUSIPN/A CIK1510964 Webwww.cvsciences.com Phone866-290-2157Debt Debt-to-Equity Ratio0.36 Current Ratio2.17 Quick Ratio1.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$53.70 million Price / Sales1.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book2.59Profitability EPS (Most Recent Fiscal Year)($0.17) Net Income$-16,610,000.00 Net Margins-26.31% Return on Equity-40.55% Return on Assets-23.71%Miscellaneous Employees78 Outstanding Shares99,852,000Market Cap$74.89 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable OTC:CVSI Rates by TradingView Receive CVSI News and Ratings via Email Sign-up to receive the latest news and ratings for CVSI and its competitors with MarketBeat's FREE daily newsletter. CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions How has CV Sciences' stock been impacted by COVID-19 (Coronavirus)? CV Sciences' stock was trading at $0.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CVSI stock has increased by 25.0% and is now trading at $0.75. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of CV Sciences? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CV Sciences. When is CV Sciences' next earnings date? CV Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for CV Sciences. How were CV Sciences' earnings last quarter? CV Sciences Inc (OTCMKTS:CVSI) released its quarterly earnings results on Friday, May, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.02. The firm earned $8.27 million during the quarter, compared to the consensus estimate of $6 million. CV Sciences had a negative return on equity of 40.55% and a negative net margin of 26.31%. View CV Sciences' earnings history. What price target have analysts set for CVSI? 3 equities research analysts have issued 1-year target prices for CV Sciences' stock. Their forecasts range from $1.70 to $5.00. On average, they anticipate CV Sciences' stock price to reach $3.35 in the next year. This suggests a possible upside of 346.7% from the stock's current price. View analysts' price targets for CV Sciences. Has CV Sciences been receiving favorable news coverage? News coverage about CVSI stock has been trending very negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CV Sciences earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutCV Sciences. Who are some of CV Sciences' key competitors? Some companies that are related to CV Sciences include Verrica Pharmaceuticals (VRCA), MannKind (MNKD), Concert Pharmaceuticals (CNCE), AMAG Pharmaceuticals (AMAG), Menlo Therapeutics (MNLO), Ovid Therapeutics (OVID), Neptune Wellness Solutions (NEPT), CymaBay Therapeutics (CBAY), ProQR Therapeutics (PRQR), Fortress Biotech (FBIO), Affimed (AFMD), Chiasma (CHMA), Spero Therapeutics (SPRO), Hookipa Pharma (HOOK) and REDHILL BIOPHAR/S (RDHL). View all competitors. What other stocks do shareholders of CV Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), KushCo (KSHB), Aphria (APHA), OrganiGram (OGI), Tilray (TLRY), GW Pharmaceuticals PLC- (GWPH) and Medical Marijuana (MJNA). Who are CV Sciences' key executives? CV Sciences' management team includes the following people: Mr. Joseph D. Dowling, CEO, Sec. & Director (Age 62)Mr. Michael J. Mona III, Co-Founder, COO & Director (Age 33)Mr. Joerg Grasser, CFO, Chief Accounting Officer & DirectorDr. Joseph Maroon, MD & DirectorDr. Douglas MacKay ND, Sr. VP of Scientific & Regulatory Affairs and Director What is CV Sciences' stock symbol? CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI." How do I buy shares of CV Sciences? Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CV Sciences' stock price today? One share of CVSI stock can currently be purchased for approximately $0.75. How big of a company is CV Sciences? CV Sciences has a market capitalization of $74.89 million and generates $53.70 million in revenue each year. The company earns $-16,610,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. CV Sciences employs 78 workers across the globe. What is CV Sciences' official website? The official website for CV Sciences is www.cvsciences.com. How can I contact CV Sciences? CV Sciences' mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 866-290-2157 or via email at [email protected] This page was last updated on 6/5/2020 by MarketBeat.com Staff
